Eureka Therapeutics Inc.

Duarte, California

OncologymRNAPhase II

What changed

Phase II trial registered: ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma

1w agoTrial registeredJul 6, 2026Source filing (opens the source filing in a new tab)

Momentum

93no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Grant
R01 · $545k · non-dilutive
Jun 1, 2026
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI YANG, FENG-CHUN · NCI · award ends May 31, 2031 · The molecular mechanisms underlying PHF6-mutation-mediated hematologic malignancies
NIH RePORTER · NIH RePORTER 11333545 (opens the source filing in a new tab)
Grant
R01 · $684k · non-dilutive
Feb 15, 2026
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI PETER, INGA · NIDDK · award ends Dec 31, 2029 · EYA1 as a novel regulator of HIV-induced end stage kidney disease
NIH RePORTER · NIH RePORTER 11328440 (opens the source filing in a new tab)
Trial
NA registered
Feb 1, 2026
Pain Management · NOT_YET_RECRUITING · sponsor: Chinese PLA General Hospital · Anesthetic Management Guided by the Medstrom Instrument
ClinicalTrials.gov · NCT07089017 (opens the source filing in a new tab)
Grant
R01 · $704k · non-dilutive
Sep 19, 2025
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI PETER, INGA · NIA · award ends Jun 30, 2030 · Clonal hematopoiesis, epigenetic changes, social determinants of health, and behavioral risk factors as predictors of accelerated aging in HIV
NIH RePORTER · NIH RePORTER 11255868 (opens the source filing in a new tab)
Trial
NA registered
Jun 30, 2025
Hypoxemia · ENROLLING_BY_INVITATION · sponsor: Chinese PLA General Hospital · Extubation Safety Via Microstream EtCO₂ (IPI) Monitoring
ClinicalTrials.gov · NCT06975553 (opens the source filing in a new tab)
Grant
U24 · $424k · non-dilutive
May 1, 2025
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI WANG, PEI · NCI · award ends Apr 30, 2026 · Proteogenomic translator for cancer biomarker discovery towards precision medicine
NIH RePORTER · NIH RePORTER 11324428 (opens the source filing in a new tab)
Grant
R01 · $485k · non-dilutive
May 1, 2023
BAYLOR COLLEGE OF MEDICINE · PI YANG, FENG · NCI · award ends Apr 30, 2028 · COP1 REGULATION OF AR SIGNALING AND PROSTATE CANCER GROWTH AND THERAPY RESISTANCE
NIH RePORTER · NIH RePORTER 11321567 (opens the source filing in a new tab)
Trial
PHASE1/PHASE2 registered
Jul 19, 2022
Hepatoblastoma, Hepatocellular Carcinoma (HCC), Liver Neoplasms, Metastatic Liver Cancer, Liver Cancer, HEMNOS · RECRUITING · sponsor: Eureka Therapeutics Inc. · ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
ClinicalTrials.gov · NCT04634357 (opens the source filing in a new tab)
Grant
U24 · $815k · non-dilutive
Jul 1, 2022
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI WANG, PEI · NCI · award ends Apr 30, 2027 · Proteogenomic translator for cancer biomarker discovery towards precision medicine
NIH RePORTER · NIH RePORTER 11323117 (opens the source filing in a new tab)
Grant
R01 · $841k · non-dilutive
Dec 1, 2021
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HE, JOHN CIJIANG · NIDDK · award ends Nov 30, 2026 · Elucidating the Molecular Mechanisms that Mediate DKD Progression in Patients Living with HIV
NIH RePORTER · NIH RePORTER 11235106 (opens the source filing in a new tab)
Trial
PHASE1 registered
Apr 14, 2021
Hepatocellular Carcinoma, Liver Cancer, Liver Neoplasm, Metastatic Liver Cancer · TERMINATED · sponsor: Eureka Therapeutics Inc. · Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)
ClinicalTrials.gov · NCT04502082 (opens the source filing in a new tab)
Grant
T32 · $224k · non-dilutive
Aug 1, 2011
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI YANG, FENG-CHUN · NCI · award ends Jul 31, 2027 · Cancer Biology Training Program
NIH RePORTER · NIH RePORTER 11145635 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the trial record at 0.99name similarity 100% · semantic similarity 88% · shared principal investigator / founder · same therapeutic area
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75principal investigator PETER, INGA is named on this company's filings
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
new_entity links the trial record at 0.41same therapeutic area

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Phase II trial registered: ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
1w agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
1w agoTrial recruitingSource (opens the source filing in a new tab)
NIH R01 · $0.5M · The molecular mechanisms underlying PHF6-mutation-mediated hematologic malignancies
7w agoNew grantSource (opens the source filing in a new tab)
NIH U24 · $0.8M · Proteogenomic translator for cancer biomarker discovery towards precision medicine
2mo agoGrant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.5M · COP1 REGULATION OF AR SIGNALING AND PROSTATE CANCER GROWTH AND THERAPY RESISTANCE
3mo agoGrant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.7M · EYA1 as a novel regulator of HIV-induced end stage kidney disease
5mo agoNew grantSource (opens the source filing in a new tab)
Study registered, no phase assigned: Extubation Safety Via Microstream EtCO₂ (IPI) Monitoring
5mo agoTrial registeredSource (opens the source filing in a new tab)
Study registered, no phase assigned: Anesthetic Management Guided by the Medstrom Instrument
5mo agoTrial registeredSource (opens the source filing in a new tab)
NIH R01 · $0.8M · Elucidating the Molecular Mechanisms that Mediate DKD Progression in Patients Living with HIV
6mo agoGrant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.7M · Clonal hematopoiesis, epigenetic changes, social determinants of health, and behavioral risk factors as predictors of accelerated aging in HIV
10mo agoNew grantSource (opens the source filing in a new tab)
NIH U24 · $0.4M · Proteogenomic translator for cancer biomarker discovery towards precision medicine
10mo agoGrant renewalSource (opens the source filing in a new tab)
Phase I trial registered: Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)
10mo agoTrial registeredSource (opens the source filing in a new tab)
NIH T32 · $0.2M · Cancer Biology Training Program
11mo agoGrant renewalSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

R01 · $545k · non-dilutive

R01 · $684k · non-dilutive

NA registered

R01 · $704k · non-dilutive

NA registered

U24 · $424k · non-dilutive

R01 · $485k · non-dilutive

PHASE1/PHASE2 registered

U24 · $815k · non-dilutive

R01 · $841k · non-dilutive

PHASE1 registered

T32 · $224k · non-dilutive